Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk A/S : Share repurchase programme (Form 6-K)

09/13/2021 | 09:32am EDT

Novo Nordisk A/S - Share repurchase programme

Bagsværd, Denmark, 13 September 2021 - On 4 August 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the 'Safe Harbour Rules'). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021.

Under the programme initiated 4 August 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.3 billion in the period from 5 August 2021 to 1 November 2021.

Since the announcement 6 September 2021, the following transactions have been made:

Number of

B shares

Average

purchase price

Transaction

value, DKK

Accumulated, last announcement 1,781,000 1,153,238,093
6 September 2021 82,000 636.54 52,196,094
7 September 2021 81,000 636.82 51,582,063
8 September 2021 81,000 635.78 51,498,394
9 September 2021 81,000 631.30 51,135,138
10 September 2021 81,000 624.34 50,571,227
Accumulated under the programme 2,187,000 1,410,221,010

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

Page 2 of 2

Transactions related to Novo Nordisk's incentive programmes have resulted in a net transfer from Novo Nordisk of six B shares in the period from 6 September 2021 to 10 September 2021. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 19,707,880 B shares of DKK 0.20 as treasury shares, corresponding to 0.9% of the share capital. The total amount of A and B shares in the company is 2,310,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 18 billion during a 12- month period beginning 3 February 2021. As of 10 September 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 20,901,414 B shares at an average share price of DKK 492.63 per B share equal to a transaction value of DKK 10,296,579,986.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:
Mette Kruse Danielsen +45 3079 3883 mkd@novonordisk.com
Michael Bachner (US) +1 609 664 7308 mzyb@novonordisk.com
Investors:
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com
Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com
Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:
www.novonordisk.com
CVR no:

24 25 67 90

Company announcement No 57 / 2021

Disclaimer

Novo Nordisk A/S published this content on 13 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 September 2021 13:31:02 UTC.


ę Publicnow 2021
All news about NOVO NORDISK A/S
10/25NOVO NORDISK A/S : Share repurchase programme - Form 6-K
PU
10/20Cigna's pharmacy benefit unit to prefer cheaper insulin drug from Viatris
RE
10/18NOVO NORDISK A/S : Share repurchase programme - Form 6-K
PU
10/18NOVO NORDISK A/S : – Share repurchase programme
AQ
10/18NOVO NORDISK : Gets a Buy rating from Barclays
MD
10/14NOVO NORDISK : Buy rating from Goldman Sachs
MD
10/12NOVO NORDISK A/S : Share repurchase programme - Form 6-K
PU
10/05NOVO NORDISK A/S : Share repurchase programme (Form 6-K)
PU
10/05Xeris Pharmaceuticals, Inc. completed the acquisition of Strongbridge Biopharma plc fro..
CI
10/04NOVO NORDISK A/S : – Share repurchase programme
AQ
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2021 138 B 21 462 M 21 462 M
Net income 2021 46 476 M 7 253 M 7 253 M
Net cash 2021 6 424 M 1 003 M 1 003 M
P/E ratio 2021 33,7x
Yield 2021 1,46%
Capitalization 1 559 B 243 B 243 B
EV / Sales 2021 11,3x
EV / Sales 2022 10,2x
Nbr of Employees 45 971
Free-Float 69,8%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | MarketScreener
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 681,30 DKK
Average target price 613,52 DKK
Spread / Average Target -9,95%
EPS Revisions
Managers and Directors
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Executive VP & Head-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S59.69%243 351
JOHNSON & JOHNSON4.26%431 938
ROCHE HOLDING AG15.61%338 364
PFIZER, INC.17.25%241 929
ELI LILLY AND COMPANY45.14%222 158
MERCK & CO., INC.-0.17%206 712